These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32385928)

  • 1. Doppler-based predictive model for methotrexate resistance in low-risk gestational trophoblastic neoplasia with myometrial invasion: prospective study of 147 patients.
    Qin J; Zhang S; Poon L; Pan Z; Luo J; Yu N; Wang L; Wu X; Cheng X; Xie X; Lu Y; Lu W
    Ultrasound Obstet Gynecol; 2021 May; 57(5):829-839. PubMed ID: 32385928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transvaginal ultrasound predicts delayed response to chemotherapy and drug resistance in stage I low-risk trophoblastic neoplasia.
    Cavoretto P; Gentile C; Mangili G; Garavaglia E; Valsecchi L; Spagnolo D; Montoli S; Candiani M
    Ultrasound Obstet Gynecol; 2012 Jul; 40(1):99-105. PubMed ID: 22262502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uterine artery pulsatility index: a predictor of methotrexate resistance in gestational trophoblastic neoplasia.
    Agarwal R; Harding V; Short D; Fisher RA; Sebire NJ; Harvey R; Patel D; Savage PM; Lim AK; Seckl MJ
    Br J Cancer; 2012 Mar; 106(6):1089-94. PubMed ID: 22374461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doppler study of myometrium in invasive gestational trophoblastic disease.
    Oguz S; Sargin A; Aytan H; Kelekci S; Dumanli H
    Int J Gynecol Cancer; 2004; 14(5):972-9. PubMed ID: 15361211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uterine artery pulsatility index and serum BMP-9 predict resistance to methotrexate therapy in gestational trophoblastic neoplasia: A cohort study.
    Harvey RA; Elias KM; Lim A; Bercow A; Short D; Horowitz NS; Berkowitz RS; Agarwal R; Seckl MJ
    Curr Probl Cancer; 2021 Feb; 45(1):100622. PubMed ID: 32800689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements.
    You B; Harvey R; Henin E; Mitchell H; Golfier F; Savage PM; Tod M; Wilbaux M; Freyer G; Seckl MJ
    Br J Cancer; 2013 May; 108(9):1810-6. PubMed ID: 23591194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].
    Chen YX; Shen YM; Qian JH; Xie X
    Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2109-12. PubMed ID: 16313819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GestaTIonal TrophoblAstic NeoplasIa Ultrasound assessMent: TITANIUM study.
    Verri D; Pasciuto T; Epstein E; Fruscio R; Mascilini F; Moro F; Scambia G; Valentin L; Testa AC
    Int J Gynecol Cancer; 2019 Sep; 29(7):1216-1220. PubMed ID: 31248946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement.
    Hoeijmakers YM; Eysbouts YK; Massuger LFAG; Dandis R; Inthout J; van Trommel NE; Ottevanger PB; Thomas CMG; Sweep FCGJ
    Gynecol Oncol; 2021 Dec; 163(3):531-537. PubMed ID: 34602288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the Predictive Value of Modeled Human Chorionic Gonadotrophin Residual Production in Low-Risk Gestational Trophoblastic Neoplasia Patients Treated in NRG Oncology/Gynecologic Oncology Group-174 Phase III Trial.
    You B; Deng W; Hénin E; Oza A; Osborne R
    Int J Gynecol Cancer; 2016 Jan; 26(1):208-15. PubMed ID: 26569059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of weekly intramuscular methotrexate in the treatment of low risk gestational trophoblastic neoplasia.
    Hasanzadeh M; Tabari A; Homae F; Shakeri M; Bakhshandeh T; MadaniSani F
    J Cancer Res Ther; 2014; 10(3):646-50. PubMed ID: 25313754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias.
    You B; Pollet-Villard M; Fronton L; Labrousse C; Schott AM; Hajri T; Girard P; Freyer G; Tod M; Tranchand B; Colomban O; Ribba B; Raudrant D; Massardier J; Chabaud S; Golfier F
    Ann Oncol; 2010 Aug; 21(8):1643-1650. PubMed ID: 20154304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uterine artery pulsatility index improves prediction of methotrexate resistance in women with gestational trophoblastic neoplasia with FIGO score 5-6.
    Sita-Lumsden A; Medani H; Fisher R; Harvey R; Short D; Sebire N; Savage P; Lim A; Seckl MJ; Agarwal R
    BJOG; 2013 Jul; 120(8):1012-5. PubMed ID: 23759086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sonographic characteristics of post-molar gestational trophoblastic neoplasia at diagnosis and during follow-up, and relationship with methotrexate resistance.
    Epstein E; Joneborg U
    Ultrasound Obstet Gynecol; 2020 Nov; 56(5):759-765. PubMed ID: 31909527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Combination Therapy with Actinomycin D and Methotrexate in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
    Kang HL; Zhao Q; Yang SL; Duan W
    Chemotherapy; 2019; 64(1):42-47. PubMed ID: 31163446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of an online tool for early prediction of the failure-risk in gestational trophoblastic neoplasia patients treated with methotrexate.
    Dekeister K; Bolze PA; Tod M; Tod R; Massardier J; Lotz JP; Hajri T; Colomban O; Seckl MJ; Osborne R; Freyer G; Golfier F; You B
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):15-24. PubMed ID: 32500221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Doppler ultrasound useful for evaluating gestational trophoblastic disease?
    Lin LH; Bernardes LS; Hase EA; Fushida K; Francisco RP
    Clinics (Sao Paulo); 2015 Dec; 70(12):810-5. PubMed ID: 26735221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for methotrexate resistance in low-risk gestational trophoblastic neoplasia patients (FIGO score 0-4).
    Jin T; Zhou Z; Lin M; Yuan S; Xue Y; Yin T; Xu R; Chen B; Zhang J; Sun J; Li X; Hu Y; Chen L; Wang H
    Am J Cancer Res; 2024; 14(3):1353-1362. PubMed ID: 38590416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.
    Maestá I; Nitecki R; Horowitz NS; Goldstein DP; de Freitas Segalla Moreira M; Elias KM; Berkowitz RS
    Gynecol Oncol; 2018 Jan; 148(1):161-167. PubMed ID: 29092742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of chest computed tomography findings in the evaluation and treatment of persistent gestational trophoblastic neoplasia.
    Gamer EI; Garrett A; Goldstein DP; Berkowitz RS
    J Reprod Med; 2004 Jun; 49(6):411-4. PubMed ID: 15283046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.